It has been reported that the VEGF pathway is implicated in EGFR-TKI resistance and that the addition of bevacizumab to erlotinib substantially improved PFS (17.9 months vs. 11.2 months) compared with erlotinib alone in EGFR-mutant NSCLC patients [196, 197]. Here, EGFR is linked to non-small cell lung carcinoma.